Dupont Bo, Hsu Katharine C
Immunology Program, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA.
Curr Opin Immunol. 2004 Oct;16(5):634-43. doi: 10.1016/j.coi.2004.07.013.
Identification of inhibitory killer Ig-like receptor (KIR) genes and their cognate human leukocyte antigen (HLA) class I ligands in donor-recipient pairs for patients undergoing haematopoietic stem cell transplantation (HCT) as treatment for haematopoietic malignancies has recently gained considerable interest. One incentive for these studies is to identify potential donors who are not HLA identical with the recipient but who still could serve as acceptable and potentially preferred donors based on their KIR genotype. It is demonstrated that a majority of individuals have at least one inhibitory KIR gene for which they lack the cognate HLA class I ligand. Therefore, the clinical benefits conferred by 'missing KIR ligand' might not be limited only to HLA mismatched donor-recipient combinations but may be applicable also to HLA identical transplants and even autologous HCT.
在接受造血干细胞移植(HCT)治疗造血系统恶性肿瘤的患者供受者对中,鉴定抑制性杀伤细胞免疫球蛋白样受体(KIR)基因及其同源人类白细胞抗原(HLA)I类配体,最近引起了广泛关注。这些研究的一个动机是识别与受者HLA不匹配,但基于其KIR基因型仍可作为可接受且可能更优供者的潜在供者。已证明大多数个体至少有一个抑制性KIR基因,而他们缺乏与之对应的HLA I类配体。因此,“缺失KIR配体”带来的临床益处可能不仅限于HLA错配的供受者组合,也可能适用于HLA匹配的移植甚至自体HCT。